ENSCW (Ensysce Biosciences) Total Assets: $2.17 Mil (As of Mar. 2026)


ENSCW Ensysce Biosciences Inc ENSCW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Total Assets?

Ensysce Biosciences ENSCW -9.20% 23 Total Assets is $2.17 Mil as of Mar. 2026. GuruFocus rates ENSCW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Ensysce Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $2.17 Mil.

During the past 12 months, Ensysce Biosciences's average Total Assets Growth Rate was 50.00% per year. During the past 3 years, the average Total Assets Growth Rate was 4.70% per year. During the past 5 years, the average Total Assets Growth Rate was 42.30% per year.

During the past 6 years, Ensysce Biosciences's highest 3-Year average Total Assets Growth Rate was 115.60%. The lowest was -20.40%. And the median was 4.70%.

Total Assets is connected with ROA %. Ensysce Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -295.72%. Total Assets is also linked to Revenue through Asset Turnover. Ensysce Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Ensysce Biosciences  (OTCPK:ENSCW) Total Assets Explanation

Total Assets is connected with ROA %.

Ensysce Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-14.224/( (7.452+2.168)/ 2 )
=-14.224/4.81
=-295.72 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Ensysce Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (7.452+2.168)/ 2 )
=0/4.81
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Ensysce Biosciences Total Assets Related Terms

Ensysce Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Ensysce Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensysce Biosciences Total Assets Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 16.42 5.89 2.71 5.60 7.45

Ensysce Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.61 5.57 3.18 7.45 2.17
ENSCW
23GF Score
Ensysce Biosciences Inc ENSCW
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Ensysce Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=2.885+4.568
=7.45

Ensysce Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-0.669+2.837
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2.17 Mil mean?
Ensysce Biosciences (ENSCW) has a Total Assets of $2.17 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Ensysce Biosciences and its competitors.
Is Ensysce Biosciences' Total Assets too high?
Ensysce Biosciences' current Total Assets is $2.17 Mil. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' Total Assets compare to PPCB and ACUT?
Ensysce Biosciences' Total Assets of $2.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Ensysce Biosciences and its competitors. Ensysce Biosciences's current Total Assets is $2.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSCW) has a current Total Assets of $2.17 Mil. The current Total Assets is $2.17 Mil. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Ensysce Biosciences (ENSCW), the current Total Assets is $2.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ensysce Biosciences Business Description

Other Exchanges ENSC:USA
Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSCW

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price